|
Short-duration Treatment With Elbasvir/Grazoprevir and Sofosbuvir for
Hepatitis C: A Randomized Trial.
Lawitz E, Poordad F, Gutierrez JA, et al
Hepatology.
2016 Oct 22.
Abstract
Real life Egyptian experience of efficacy and safety of
Simeprevir\ Sofosbuvir therapy in 6211 chronic HCV genotype IV infected
patients
Eletreby R, Elakel W, Said M, et al
Liver Int. 2016 Oct 6.
Abstract
Sofosbuvir and ribavirin for six weeks is not effective among people with
recent HCV infection: The DARE-C II study.
Martinello M, Gane E, Hellard M,
et al
Hepatology.
2016 Sep 17.
Abstract
Comparison of the Abbott RealTime HCV and Roche COBAS Ampliprep/COBAS TaqMan
HCV assays for the monitoring of sofosbuvir-based therapy.
Ogawa
E, Furusyo N, Murata M, et al
Antivir Ther.
2016 Sep 15
Abstract
Cost-utility analysis of sofosbuvir for the treatment of genotype 2 chronic
hepatitis C in Japan.
Igarashi
A, Tang W, Cure S,
et al
Curr Med Res Opin. 2016 Sep
8:1-10.
Abstract
Effectiveness and tolerability of simeprevir and sofosbuvir in nontransplant
and post-liver transplant patients with hepatitis C genotype 1.
Lutchman G, Nguyen NH, Chang CY,
et al
Aliment Pharmacol Ther.
2016 Aug 10.
Abstract
FULL-TEXT PDF ARTICLE
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients with Genotype 1
Hepatitis C Virus Infection in an Open-label, Phase 2 Trial
Lawitz E, Reau N, Hinestrosa F, et al
Gastroenterology.
2016 Jul 30.
Paper
FULL-TEXT PDF ARTICLE
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients with HCV
Genotype 2, 3, 4, or 6 Infections in an Open-label, Phase 2 Trial.
Gane E, Kowdley KV, Pound D, et al
Gastroenterology.
2016 Jul 30.
Paper
Sofosbuvir-Based Therapy for Genotype 4 HCV Recurrence Post-Liver Transplant
Treatment-Experienced Patients.
Ajlan A, Al-Jedai A, Elsiesy H,
et al
Can J Gastroenterol Hepatol.
2016;2016:2872371.
Abstract
Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir is
Associated With High Efficacy and Improvement of Patient-Reported Outcomes
in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From
Astral-2 and 3 Clinical Trials.
Younossi ZM, Stepanova
M, Sulkowski M,
et al
Clin Infect Dis.
2016 Jul 20. pii: ciw496
Abstract
FULL-TEXT ARTICLE
Sofosbuvir/velpatasvir: A promising combination.
Bonaventura A, Montecucco F.
World J Hepatol.
2016 Jul 8;8(19):785-9.
Paper
Treatment of HCV genotype 2 with sofosbuvir and ribavirin results in lower SVR
rates in real life than expected from clinical trials.
Tacke F, Günther R, Buggisch P,
et al
Liver Int.
2016 Jul 18.
Abstract
FULL-TEXT ARTICLE
Successful sofosbuvir treatment with ribavirin dose reduction for chronic hepatitis C virus genotype 2 infection in a patient with ulcerative colitis: a case report.
Ohta Y, Kanda T, Katsuno T, Yasui S, et al
BMC Gastroenterol. 2016 Jul 11;16(1):66.
Paper |
Ledipasvir and sofosbuvir for HCV-infection in patients coinfected with HBV.
Gane EJ, Hyland RH, An D, et al
Antivir Ther. 2016 Jul 1
Abstract
Role of ledipasvir/sofosbuvir combination for genotype 1 hepatitis C virus infection.
Sundaram V, Kowdley KV.
Hepat Med. 2016 Jun 28;8:75-80.
Abstract
Sofosbuvir-based treatment of hepatitis C with severe fibrosis (METAVIR F3/F4) after liver transplantation: Results from the CO23 ANRS CUPILT study.
Dumortier J, Leroy V, Duvoux C, et al
Liver Transpl. 2016 Jun 27.
Abstract
Effectiveness and safety of sofosbuvir-based regimens for chronic HCV genotype 3 infection: results of the HCV-TARGET study.
Feld JJ, Maan R, Zeuzem S, et al
Clin Infect Dis. 2016 Jun
19.
Abstract
Colitis during new direct-acting antiviral agents (DAAs) therapy with sofosbuvir, simeprevir and ribavirin for genotype 1b hepatitis C.
Izzo I, Zanotti P, Chirico C, et al
Infection. 2016 Jun 16.
Abstract
Sofosbuvir and ledipasvir improve patient-reported outcomes in patients co-infected with hepatitis C and human immunodeficiency virus.
Younossi ZM, Stepanova M, Sulkowski M, et al
J Viral Hepat. 2016 Jun 13.
Abstract
FULL-TEXT ARTICLE
Will Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World Data.
Chen GF, Wei L, Chen J, et al
PLoS One. 2016 Jun 8;11(6):e0155934.
Paper
Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Healthcare System.
Ioannou GN, Beste LA, Chang MF, et al
Gastroenterology. 2016 Jun 4
Abstract
A UHPLC-MS/MS method for the quantification of direct antiviral agents simeprevir, daclatasvir, ledipasvir, sofosbuvir/GS-331007, dasabuvir, ombitasvir and paritaprevir, together with ritonavir, in human plasma.
Ariaudo A, Favata F, De Nicolò A. et al
J Pharm Biomed Anal. 2016 Jun 5;125:369-75.
Abstract
Quantification of sofosbuvir in human serum by liquid chromatography with negative ionization mass spectrometry using the parent peak and its source-induced fragment: Application to a bioequivalence study.
Bahrami MT, Mohammadi B, Miraghaei S, et al
J Sep Sci. 2016 Jun 3.
Abstract
Multicentre experience using daclatasvir and sofosbuvir to treat hepatitis C recurrence after liver transplantation - The CO23 ANRS CUPILT study.
Coilly A, Fougerou-Leurent C, de Ledinghen V, et al
J Hepatol. 2016 Jun 1
Abstract
Efficacy of the Combination of Sofosbuvir, Velpatasvir, and the NS3/4A Protease Inhibitor GS-9857 in Treatment-naïve or Previously Treated Patients with HCV Genotype 1 or 3 Infections.
Gane EJ, Schwabe C, Hyland RH, Yang Y, et al
Gastroenterology. 2016 May 27.
Abstract
Clearance of HCV Virus After Fixed Dose Combination Ledipasvir/Sofosbuvir in an Adolescent Female with Decompensated Cirrhosis.
Smith SK, Rosenthal P.
J Pediatr Gastroenterol Nutr. 2016 May 27
Abstract
Efficacy of the Combination of Sofosbuvir, Velpatasvir, and the NS3/4A Protease
Inhibitor GS-9857 in Treatment-naïve or Previously Treated Patients with HCV
Genotype 1 or 3 Infections.
Gane EJ, Schwabe C, Hyland RH, et al
Gastroenterology. 2016
May 27.
Abstract
Efficacy of Sofosbuvir Plus Ribavirin in Veterans With Hepatitis C Virus Genotype 2 Infection, Compensated Cirrhosis, and Multiple Comorbidities.
Ho SB, Monto A, Peyton A, et al
Clin Gastroenterol Hepatol. 2016 May 26.
Abstract
Resistance Analyses of Japanese Hepatitis C-Infected Patients Receiving Sofosbuvir or Ledipasvir/Sofosbuvir Containing Regimens in Phase 3 Studies.
Mizokami M, Dvory-Sobol H, Izumi N, et al
J Viral Hepat. 2016 May 15.
Abstract
Safety, Efficacy, and Tolerability of Sofosbuvir and Ribavirin in Management of Recurrent Hepatitis C Virus Genotype 4 After Living Donor Liver Transplant in Egypt: What Have We Learned so far?
Dabbous HM, Montasser IF, Sakr MA,
et al
Hepat Mon. 2016 Apr 30;16(5):e35339.
Abstract
Emergence of HCV resistance-associated variants in patients failing sofosbuvir-based regimens: an observational cohort.
André-Garnier E, Ribeyrol O, Gournay J, et al
Antivir Ther. 2016 Apr 29.
Abstract
Treatment of severe recurrent hepatitis C after liver transplantation in HIV infected patients using sofosbuvir-based therapy.
Campos-Varela I, Moreno A, Morbey A. et al
Aliment Pharmacol Ther. 2016 Apr 21
Abstract
Barrier-independent, fitness-associated differences in sofosbuvir-efficacy against hepatitis C virus.
Gallego I, Sheldon J, Moreno E, et al
Antimicrob Agents Chemother. 2016 Apr 11.
Abstract
Sofosbuvir plus ribavirin in Asian patients with chronic genotype 2 hepatitis C virus infection: history of a success?
Sáez-Royuela F, Badia E.
Liver Int. 2016 Apr 5.
Abstract
FULL-TEXT ARTICLE
Simeprevir and Sofosbuvir Combination Treatment in a Patient with HCV Cirrhosis and HbS Beta 0-Thalassemia: Efficacy and Safety despite Baseline Hyperbilirubinemia
Papadopoulos N, Deutsch M, Georgalas A, et al
Case Rep Hematol. 2016;2016:7635128
Paper
Sofosbuvir and Simeprevir without Ribavirin Effectively Treat Hepatitis C Virus Genotype 1 Infection after Liver Transplantation in a Two-Center Experience.
Jackson WE, Hanouneh M, Apfel T, et al
Clin Transplant. 2016 Mar 28.
Abstract
Severe Pulmonary Arterial Hypertension in Patients Treated for Hepatitis C With Sofosbuvir
Renard S, Borentain P, Salaun E, Benhaourech S, et al
Chest. 2016 Mar;149(3):e69-73
Abstract
Hepatic decompensation/serious adverse events in post-liver transplantation recipients on sofosbuvir for recurrent hepatitis C virus.
Patel N, Bichoupan K, Ku L, et al
World J Gastroenterol. 2016 Mar 7;22(9):2844-54.
Abstract
Sofosbuvir/Velpatasvir Improves Patient-Reported Outcomes in HCV Patients: Results from ASTRAL-1 Placebo-Controlled Trial
Younossi ZM, Stepanova M, Feld J, et aj
J Hepatol. 2016 Mar 5
Abstract
Sofosbuvir-containing regimen for HCV infection in hemodialysis patients: 400 mg daily or only on the day of hemodialysis.
Desnoyer A, Pospai D, Lê MP, et al
J Hepatol. 2016 Mar 4.
Abstract.
Sofosbuvir-Based Antiviral Therapy Is Highly Effective In Recurrent Hepatitis C in Liver Transplant Recipients: Canadian Multicenter "Real-Life" Experience.
Faisal N, Bilodeau M, Aljudaibi B, et al
Transplantation. 2016 Mar 4.
Abstract.
FULL-TEXT ARTICLE
Lower response to simeprevir and sofosbuvir in HCV genotype 1 in routine practice compared with clinical trials.
Yee BE, Nguyen NH, Jin M, et al
BMJ Open Gastroenterol. 2016 Mar 2;3(1):e000056
Paper
Treatment Adherence and Virologic Response Rates in HCV Infected Persons Treated with Sofosbuvir-based Regimens: Results from ERCHIVES.
Butt AA, Yan P, Shaikh OS, et al
Liver Int. 2016 Mar 1.
Abstract.
Retreatment with sofosbuvir and simeprevir of patients with HCV GT1 or 4 who previously failed a daclatasvir-containing regimen.
Hézode C, Chevaliez S, Scoazec G, et al
Hepatology. 2016 Feb 8.
Abstract.
Simeprevir and Sofosbuvir (SMV-SOF) for 12 Weeks for the Treatment of Chronic Hepatitis C Genotype 1 Infection: A Real World (Transplant) Hepatology Practice Experience
Pillai AA, Wedd J, Norvell JP, et al
Am J Gastroenterol. 2016 Feb 2
Abstract.
FULL-TEXT ARTICLE
Simeprevir Plus Sofosbuvir (12 and 8 Weeks) in HCV Genotype 1-Infected Patients Without Cirrhosis: OPTIMIST-1, a Phase 3, Randomized Study.
Kwo P, Gitlin N, Nahass R, Bernstein D,
et al
Hepatology. 2016 Jan 22.
Paper
Sofosbuvir treatment and hepatitis C virus infection.
Nakamura M, Kanda T, Haga Y, et al
World J Hepatol. 2016 Jan 28;8(3):183-90
Abstract
FULL-TEXT ARTICLE
Tolerability and
effectiveness of sofosbuvir and simeprevir in the post-transplant setting:
systematic review and meta-analysis.
Nguyen NH, Yee BE, Chang C,
et al
BMJ Open Gastroenterol.
2016 Jan 4;3(1):e000066.
Paper
A model-based meta-analysis of sofosbuvir-based treatments in chronic hepatitis C patients.
Pérez-Pitarch A, Guglieri-López B, Ferriols-Lisart R, Merino-Sanjuán M.
Int J Antimicrob Agents. 2016 Jan 12. pii: S0924-8579(16)00003-0.
Abstract
Interferon-free treatment with sofosbuvir/daclatasvir achieves sustained virologic response in 100% of HIV/HCV-coinfected patients with advanced liver disease.
Mandorfer M, Schwabl P, Steiner S, et al
AIDS. 2016 Jan 11.
Abstract
Adverse Events Associated with Ribavirin in Sofosbuvir Based Therapies for Patients with Chronic Hepatitis C: A Community Practice Experience.
Tong MJ, Chang PW, Huynh TT, et al
J Dig Dis. 2016 Jan 8.
Abstract
Successful sofosbuvir-based therapy in HIV/hepatitis C virus coinfected liver transplant recipients with recurrent hepatitis C virus infection.
Grant JL, Hawkins C, Brooks H, et al
AIDS. 2016 Jan 2;30(1):93-98.
Abstract
FULL-TEXT ARTICLE
Budget impact analysis of sofosbuvir-based regimens for the treatment of HIV/HCV-coinfected patients in northern Italy: a multicenter regional simulation.
Cenderello G, Artioli S, Viscoli C, et al
Clinicoecon Outcomes Res. 2015 Dec 31;8:15-21.
Paper
FULL-TEXT ARTICLE
Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in Korea.
Cho Y, Cho EJ, Lee JH, et al
Clin Mol Hepatol. 2015 Dec;21(4):358-64.
Paper
Defining the possibilities: is short duration treatment of chronic hepatitis C genotype 1 with sofosbuvir-containing regimens likely to be as effective as current regimens?
Nafisi S, Roy S, Gish R, et al
Expert Rev Anti Infect Ther. 2015 Dec 14:1-16
Abstract
The discovery of sofosbuvir: a revolution for therapy of chronic hepatitis C.
Gentile I, Maraolo AE, Buonomo AR, et al
Expert Opin Drug Discov. 2015 Dec;10(12):1363-77
Abstract
Sofosbuvir-based Regimens in Clinical Practice Achieve SVR Rates Closer to Clinical Trials: Results from ERCHIVES.
Butt AA, Yan P, Shaikh OS, et al
Liver Int. 2015 Nov 29.
Abstract
Efficacy and Safety of Sofosbuvir-Based Antiviral Therapy to Treat Hepatitis C Virus Infection After Kidney Transplantation.
Kamar N, Marion O, Rostaing L, et al
Am J Transplant. 2015 Nov 20.
Abstract
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.
Feld JJ, Jacobson IM, Hézode C, et al
N Engl J Med. 2015 Nov 16.
Abstract
FULL-TEXT ARTICLE
Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis.
Curry MP, O'Leary JG, Bzowej N, et al
N Engl J Med. 2015 Nov 16
Paper
Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized Trial.
Pianko S, Flamm SL, Shiffman ML, et al
Ann Intern Med. 2015 Nov 10.
Abstract
Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection: A Randomized Trial.
Everson GT, Towner WJ, Davis MN, et al
Ann Intern Med. 2015 Nov 10.
Abstract
Course of hepatitis C virus (HCV) RNA and HCV core antigen testing are predictors for reaching sustained virologic response in liver transplant recipients undergoing sofosbuvir treatment in a real-life setting.
Pischke S, Polywka S, Proske VM, et al
Transpl Infect Dis. 2015 Oct 20.
Abstract
Successful treatment of hepatitis C virus infection with sofosbuvir and simeprevir in the early phase of an allogeneic stem cell transplant.
Piñana JL, Serra MÁ, Hernández-Boluda JC, et al
Transpl Infect Dis. 2015 Oct 20.
Abstract
Treatment of Hepatitis C Virus-Associated Mixed Cryoglobulinemia with Sofosbuvir-Based Direct-Acting Antiviral Agents.
Sise ME, Bloom AK, Wisocky J, et al
Hepatology. 2015 Oct 17.
Abstract
Colitis Following Initiation of Sofosbuvir and Simeprevir for Genotype 1 Hepatitis C.
Sarkar S, Mitchell KA, Lim JK, et al
ACG Case Rep J. 2015 Oct 9;3(1):42-4.
Abstract
Sofosbuvir-Induced Erythrodermic Pityriasis Rubra Pilaris-Like Drug Eruption.
Cheung EJ, Jedrych JJ, English JC.
J Drugs Dermatol. 2015 Oct 1;14(10):1161-2.
Abstract
Sofosbuvir plus Simeprevir Treatment of Recurrent Genotype 1 Hepatitis C after Liver Transplant.
Punzalan CS, Barry C, Zacharias I, et al
Clin Transplant. 2015 Sep 11
Abstract
Dysregulation of Distal Cholesterol Biosynthesis in Association with Relapse and
Advanced Disease in CHC Genotype 2 and 3 Treated with Sofosbuvir and Ribavirin.
Younossi ZM, Stepanova M, Estep M, et al
J Hepatol. 2015 Sep 1.
Abstract
FULL-TEXT ARTICLE
Liver Toxicity Associated with Sofosbuvir, an NS5A Inhibitor and Ribavirin Use.
Dyson
JK, Hutchinson J, Harrison L, et al
J Hepatol. 2015 Aug 29. pii:
S0168-8278(15)00589-9.
Paper
FULL-TEXT ARTICLE
Drug Authorization for Sofosbuvir/Ledipasvir (Harvoni) for Chronic HCV Infection
in a Real-World Cohort: A New Barrier in the HCV Care Cascade.
Do A, Mittal Y, Liapakis A, et al
PLoS One. 2015 Aug
27;10(8):e0135645.
Paper
Development of sofosbuvir for the treatment of hepatitis C virus
infection.
Lawitz E, Jacobson IM, Nelson DR,
et al
Ann N Y Acad Sci.
2015 Jul 31.
Abstract
Treating Fibrosing Cholestatic Hepatitis C with
Sofosbuvir and Ribavirin: A Matched Analysis
Saab S, Jimenez M, Bau S, et al
Clin Transplant. 2015 Jul 4.
Abstract
Temporal dynamics of inflammatory cytokines/chemokines during Sofosbuvir and
Ribavirin therapy for Genotype 2 and 3 Hepatitis C infection.
Carlin
AF, Aristizabal P, Song Q, et al
Hepatology.
2015 Jul 3
Abstract
'Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of
Hepatitis C Virus Infection in the United States
Barua S, Greenwald R, Grebely J,
et al
Ann Intern Med.
2015 Jun 30
Abstract
Cost-Effectiveness of New Direct-Acting Antivirals to Prevent
Post-Liver Transplant Recurrent Hepatitis.
Cortesi PA, Mantovani LG,
Ciaccio A, et al
Am J Transplant. 2015 Jul;15(7):1817-26
Abstract
A New Standard of Care? Standard Dose Sofosbuvir in an HCV-Infected Liver
Transplant Recipient Undergoing Hemodialysis.
Perumpail
RB, Wong RJ, Pham EA, et al
Dig
Dis Sci. 2015 Jun 17.
Abstract
Efficacy of Sofosbuvir and Daclatasvir in Patients with Fibrosing
Cholestatic Hepatitis C After Liver Transplantation.
Leroy V, Dumortier J, Coilly A, et al
Clin Gastroenterol Hepatol.
2015 Jun 1
Abstract
FULL-TEXT ARTICLE
Treatment of
Recurrent Hepatitis C Genotype-4 Post-Liver Transplantation with Sofosbuvir
plus Simeprevir.
Ascha M, Ascha M, Zein NN,
Int J Organ Transplant Med.
2015;6(2):86-90.
Paper
Sofosbuvir Plus Ribavirin for Treating Egyptian Patients
With Hepatitis C Genotype 4.
Doss W, Shiha G, Hassany M, et al
Hepatol. 2015
Apr 30
Abstract |
FULL-TEXT ARTICLE
Sofosbuvir and ribavirin before liver re-transplantation for graft failure due
to recurrent hepatitis C: a case report.
Vionnet J, Pascual M, Chtioui H,
BMC Gastroenterol. 2015 Mar
26;15(1):38.
Paper
Cost-Effectiveness and Budget Impact of Hepatitis C Virus
Treatment With Sofosbuvir and Ledipasvir in the United States.
Chhatwal J, Kanwal F, Roberts MS, Dunn MA.
Ann Intern Med.
2015 Mar 17;162(6):397-406
Abstract
Perspectives of fixed daily dose of sofosbuvir and ledipasvir for
the treatment of chronic hepatitis C.
Floreani A.
Expert Opin Pharmacother. 2015 Mar 1:1-4
Abstract
Fixed-dose combination of sofosbuvir and ledipasvir for the
treatment of chronic hepatitis C genotype 1.
Kumari R, Nguyen MH.
Expert Opin Pharmacother.
2015 Feb 13:1-10
Abstract
FULL-TEXT ARTICLE
Ledipasvir and sofosbuvir: Interferon free therapy for
hepatitis C virus genotype 1 infection.
Waheed Y.
World J Virol.
2015 Feb 12;4(1):33-5.
Paper
Optimal duration to pre-liver transplantation anti-hepatitis C
treatment with direct-acting agent Sofosbuvir.
Donato MF, Malinverno
F, Monico S.
Liver Int. 2015 Feb 11.
Abstract
Sofosbuvir plus ribavirin for treatment of hepatitis C virus in
patients co-infected with HIV (PHOTON-2): a multicentre, open-label,
non-randomised, phase 3 study.
Molina JM, Orkin C,
Iser DM, et al
Lancet.
2015 Feb 3. pii: S0140-6736(14)62483-1
Abstract
Assessing safety and efficacy of sofosbuvir for the treatment of
hepatitis C.
D'Ambrosio R, Aghemo A,
Colombo M.
Expert Opin Drug Saf. 2015 Feb 3:1-12.
Abstract
A Cross-Sectional Study Comparing the Frequency of Drug
Interactions After Adding Simeprevir- or Sofosbuvir-Containing Therapy to
Medication Profiles of Hepatitis C Monoinfected Patients.
Patel N, Nasiri M, Koroglu A, et al
Infect Dis Ther. 2015 Jan 28.
Abstract
Sofosbuvir (Sovaldi°). Active against hepatitis C virus, but evaluation is
incomplete
[No
authors listed]
Prescrire Int. 2015
Jan;24(156):5-10.
Abstract
Simeprevir and Sofosbuvir for Treatment of Chronic Hepatitis C
Infection.
Childs-Kean LM, Hand EO.
Clin Ther.
2015 Jan 16. pii: S0149-2918(14)00870-4
Abstract
Sofosbuvir compassionate use program for patients with
severe recurrent hepatitis C following liver
transplantation.
Forns X, Charlton M, Denning J, et al
Hepatology.
2014
Dec 29.
Abstract
The Combination of Simeprevir and Sofosbuvir is More
Effective Than That of Peginterferon, Ribavirin, and
Sofosbuvir for Patients with Hepatitis C-related Child's
Class A Cirrhosis.
Pearlman BL, Ehleben C, Perrys M.
Gastroenterology.
2014 Dec 31. pii: S0016-5085(14)01579-0.
Abstract
Sofosbuvir-based treatment regimens for chronic, genotype 1
hepatitis C virus infection in US. Incarcerated populations: a
cost-effectiveness analysis.
Liu S, Watcha D,
Holodniy M, Goldhaber-Fiebert JD.
Ann
Intern Med. 2014 Oct 21;161(8):546-53.
Abstract
FULL-TEXT
ARTICLE
Sofosbuvir: A novel treatment option for chronic hepatitis C infection.
Bhatia HK, Singh H, Grewal N, Natt NK.
J Pharmacol Pharmacother. 2014 Oct;5(4):278-284.
Paper
Sofosbuvir with peginterferon-ribavirin for 12 weeks in
previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis.
Lawitz E, Poordad
F, Brainard DM, et al
Hepatology. 2014 Oct 16
Abstract
Concordance of Sustained Virologic Response 4, 12, and 24
Weeks Post-Treatment With Sofosbuvir-Containing Regimens for Hepatitis C
Virus.
Yoshida EM,
Sulkowski MS, Gane EJ, et al
Hepatology. 2014 Oct 14
Abstract
FULL-TEXT
ARTICLE
Sofosbuvir: A novel treatment option for chronic hepatitis C infection.
Bhatia HK, Singh H, Grewal N, Natt NK.
J Pharmacol Pharmacother. 2014
Oct;5(4):278-284.
Paper
Sofosbuvir and Ribavirin for Treatment of Compensated
Recurrent Hepatitis C Virus Infection After Liver Transplantation.
Charlton M, Gane E, Manns MP, et al
Gastroenterology. 2014 Oct 7.
Abstract
Sofosbuvir and Ribavirin Prevent Recurrence of HCV Infection
after Liver Transplantation: An Open-Label Study.
Curry MP, Forns X,
Chung RT, Terrault NA, et al.
Gastroenterology.
2014 Sep 24
Abstract
Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid
metabolism in chronic HCV, genotype-1 infected patients.
Meissner EG, Lee YJ, Osinusi A, et al
Hepatology. 2014 Sep 9
Abstract
CON Sofosbuvir and Ribavirin Use in Wait-Listed Patients with
Hepatitis C Should be Selective.
Price JC, Terrault
NA.
Liver Int. 2014 Sep
2.
Abstract
Sofosbuvir, a novel nucleotide analogue inhibitor used for
the treatment of hepatitis C virus.
Summers BB, Beavers JW, Klibanov OM.
J Pharm Pharmacol. 2014 Aug 31.
Abstract
Successful treatment with sofosbuvir of fibrosing cholestatic hepatitis C
after liver transplantation in HIV-HCV coinfected patient.
Borentain
P, Colson P, Dhiver C, et al
Antivir
Ther. 2014 Aug 8.
Abstract
FULL-TEXT
ARTICLE
Relationship
of ethnicity and overall survival in patients treated with sorafenib for
advanced hepatocellular carcinoma.
Peixoto RD, Renouf DJ, Gill S, et al
J
Gastrointest Oncol.
2014 Aug;5(4):259-64
Paper
Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in
the treatment of chronic hepatitis C virus genotype 1 infection.
Saab S, Gordon SC, Park H, et al
Aliment Pharmacol Ther.
2014 Jul 28
Abstract
Ledipasvir/Sofosbuvir administration achieves very high rate
of viral clearance in patients with HCV genotype 1 infection without
cirrhosis, regardless of ribavirin co-administration or length of treatment.
Gentile I, Borgia G.
Evid Based Med.
2014 Jul 15.
Abstract
Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C:
Potent antiviral activity but no clinical benefit if treatment is given
late.
Pellicelli AM, Montalbano M, Lionetti R, et al
Dig Liver Dis. 2014 Jul
2.
Abstract
Sofosbuvir for the treatment of chronic hepatitis C virus
infection.
Temesgen Z, Talwani R, Rizza
SA.
Drugs Today (Barc). 2014
Jun;50(6):421-434.|
Abstract
Lack of a Clinically Important Pharmacokinetic Interaction
Between Sofosbuvir or Ledipasvir and Hormonal Oral Contraceptives
Norgestimate/Ethinyl Estradiol in HCV-Uninfected Female Subjects.
German P, Moorehead
L, Pang PS, et
al
J Clin Pharmacol.
2014 Jun 13
Abstract
Sofosbuvir: A Nucleotide NS5B Inhibitor for the Treatment of Chronic
Hepatitis C Infection.
Rose
L, Bias TE, Mathias CB, et al
Ann
Pharmacother. 2014 May
8
Abstract
FULL-TEXT
ARTICLE
Sofosbuvir, a NS5B polymerase inhibitor in the treatment of
hepatitis C: a review of its clinical potential.
Stedman C.
Therap Adv Gastroenterol. 2014
May;7(3):131-140.
Paper
FULL-TEXT
ARTICLE
Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3.
Zeuzem
S, Dusheiko GM, Salupere R, et sl
N
Engl J Med. 2014 May 4.
Paper
Beyond sofosbuvir: What opportunity exists for a better
nucleoside/nucleotide to treat hepatitis C?
Sofia MJ.
Antiviral Res. 2014 May
2.
Abstract
Sofosbuvir for the treatment of chronic hepatitis C:
between current evidence and future perspectives.
Degasperi E, Aghemo A.
Hepat Med. 2014
Apr 29;6:25-33
Abstract
Sofosbuvir in the Treatment of Chronic Hepatitis C: New Dog, New Tricks.
Abraham
GM, Spooner LM.
Clin
Infect Dis. 2014 Apr 18
Abstract
Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection.
Afdhal N, Zeuzem S, Kwo P, et al
N Engl J Med.
2014 Apr 11.
Abstract
Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1
Infection.
Afdhal N, Reddy KR, Nelson DR, et al
N Engl J Med. 2014 Apr 11
Abstract
Patient-reported outcomes in chronic hepatitis C patients with cirrhosis
treated with sofosbuvir-containing regimens.
Younossi ZM, Stepanova M, Nader F, et al
Hepatology. 2014 Apr 8.
Abstract
FULL-TEXT
PDF ARTICLE
[MUST BE DOWNLOADED DIRECTLY FROM SITE)
Benefit-risk assessment of new and emerging treatments for hepatitis C:
focus on simeprevir and sofosbuvir
Gaetano JN.
Drug Healthc Patient Saf.
2014 Mar 31;
Paper
Hepatitis C virus: Here comes all-oral treatment.
Dugum M, O'Shea R.
Cleve Clin J Med.
2014 Mar;81(3):159-72.
Abstract
In Vivo Emergence of a Novel Mutant L159F/L320F in the NS5B Polymerase
Confers Low-Level Resistance to the HCV Polymerase Inhibitors
Mericitabine and Sofosbuvir.
Tong X, Le Pogam S, Li L, et al
J Infect Dis. 2014
Mar;209(5):668-75.
Abstract
Review article: the efficacy and safety of sofosbuvir, a
novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of
chronic hepatitis C virus infection.
Koff RS.
Aliment Pharmacol Ther. 2014
Mar;39(5):478-87
Abstract
Analysis of the hepatitis C viral kinetics during
administration of two nucleotide analogues: sofosbuvir (GS-7977) and
GS-0938.
Guedj J, Pang PS, Denning J,
Rodriguez-Torres M, et al
Antivir Ther. 2014 Jan 24.
Abstract
Sofosbuvir for the treatment of hepatitis C virus.
Asselah T.
Expert Opin Pharmacother. 2014
Jan;15
Abstract
Review article: the efficacy and safety of sofosbuvir, a novel, oral
nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis
C virus infection
Koff
RS.
Aliment Pharmacol Ther.
2014 Jan 6.
Abstract
IFNL4-ΔG Genotype is Associated with Slower Viral Clearance
in Hepatitis C, Genotype-1 Patients Treated with Sofosbuvir and Ribavirin.
Meissner EG, Bon D, Prokunina-Olsson L, et al
J Infect Dis. 2013 Dec 23.
Abstract
FULL-TEXT ARTICLE
Sofosbuvir
has come out of the magic box.
Alavian SM.
Hepat Mon.
201316;13(12):e16916.
Paper
Sofosbuvir with ribavirin is safe and effective in hepatitis
C genotype 1 with unfavourable pretreatment characteristics.
Ferguson MC.
Evid Based Med. 2013
Dec 12.
Abstract
Sofosbuvir (GS-7977), a pan-genotype, direct-acting antiviral for hepatitis
C virus infection.
Rodríguez-Torres M.
Expert
Rev Anti Infect Ther.
2013 Dec;11(12):1269-79.
Abstract
Effects of Sofosbuvir-based Treatment, With and
Without Interferon, on Outcome and Productivity of Patients With Chronic
Hepatitis C.
Younossi ZM, Stepanova M, Henry L, et al
Clin Gastroenterol Hepatol.
2013 Dec 5.
Abstract
Sofosbuvir (GS-7977), a pan-genotype, direct-acting antiviral for hepatitis
C virus infection.
Rodríguez-Torres M.
Expert Rev Anti Infect Ther.
2013 Dec;11(12):1269-79.
Abstract
Efficacy of Nucleotide Polymerase Inhibitor Sofosbuvir plus
the NS5A Inhibitor Ledipasvir or the NS5B Non-nucleoside Inhibitor GS-9669
Against HCV Genotype 1 Infection.
Gane EJ, Stedman CA, Hyland RH, et al
Gastroenterology. 2013 Nov 18.
Abstract
In Vivo Emergence of a Novel Mutant L159F/L320F in the NS5B
Polymerase Confers Low-Level Resistance to the HCV Polymerase Inhibitors
Mericitabine and Sofosbuvir.
Tong X, Le Pogam S, Li L,et al
J Infect Dis. 2013
Nov 11
Abstract
Sofosbuvir and ledipasvir fixed-dose combination with and
without ribavirin in treatment-naive and previously treated patients with
genotype 1 hepatitis C virus infection (LONESTAR): an open-label,
randomised, phase 2 trial.
Lawitz E, Poordad FF, Pang PS, et al
Lancet.
2013 Nov 1.
Abstract
Resistance analysis of hepatitis C virus genotype 1 prior treatment null
responders receiving daclatasvir and asunaprevir.
McPhee F, Hernandez D, Yu F, et al
Hepatology. 2013
Sep;58(3):902-11
Abstract
Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable
treatment characteristics: a randomized clinical trial.
Osinusi A, Meissner EG, Lee YJ, et al
JAMA. 2013 Aug
28;310(8):804-11
Abstract
FULL-TEXT ARTICLE
Sofosbuvir and ABT-450: Terminator of hepatitis C virus?
Zeng QL, Zhang JY, Zhang Z,
et al
World J Gastroenterol.
2013 Jun 7;19(21):3199-206
Paper
Sofosbuvir and daclatasvir combination therapy in a liver
transplant recipient with severe recurrent cholestatic hepatitis C.
Fontana RJ, Hughes EA, Bifano M, et al
Am J Transplant.
2013 Jun;13(6
Abstract
Sofosbuvir-Based Antiviral Therapy for Treatment Naïve
Hepatitis C Genotypes 1, 2, and 3.
Sharma P.
Gastroenterology.
2013 May 27.
Abstract
FULL-TEXT ARTICLE
Persistence of
resistant variants in hepatitis C virus-infected patients treated with the NS5A
replication complex inhibitor daclatasvir.
Wang C, Sun JH, O'Boyle DR 2nd, et aL
Antimicrob
Agents Chemother. 2013 May;57(5):2054-65
Paper
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for
non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C
infection:
a randomised, double-blind, phase 2 trial.
Lawitz E, Lalezari JP, Hassanein T, et al
Lancet Infect Dis.
2013 May;13(5):401-8.
Abstract |
Internet
Books and Documents
HCV
Drugs